Capsugel Launches New Drug Delivery Technology Platform

• Capsugel

Capsugel has  announced the global commercial launch of its enTRinsic^TM drug delivery technology platform. This first-of-its-kind innovation provides full enteric protection and targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract, without the need for functional coatings.

“Capsugel’s enTRinsic drug delivery technology is the result of our continued commitment to innovate for our customers,” said Amit Patel, President, Capsugel Dosage Form Solutions. “For years the industry has been searching for a fully enteric dosage form that doesn’t require functional coatings.  By leveraging Capsugel’s unique combination of formulation, polymer chemistry and manufacturing expertise, we have developed a novel solution for enteric protection and the targeted delivery of a wide range of sensitive molecules.”

Capsugel’s breakthrough technology enables oral delivery of a variety of compounds – including vaccines, proteins and peptides – using pharmaceutically approved enteric polymers. The technology is now globally available for customer projects following the successful completion of an 18-month lead-user customer-collaboration program that included feasibility studies with new and existing pharmaceutical products.

“Our lead-user program confirmed the enteric performance of our enTRinsic technology in multiple applications, as well as the viability of the formulation and manufacture of finished drug product at scale,” said Keith Hutchison, Ph.D., Senior Vice President, Research and Development, Capsugel. “We are now excited to move beyond the lead-user program and work with additional customers, while continuing to broaden the application of the technology to encompass gastric resistance, full enteric protection, and varied GI site targeting for an increasingly diverse range of APIs.”